Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Accumulated Depreciation (2020 - 2025)

Maxcyte (MXCT) has disclosed Accumulated Depreciation for 6 consecutive years, with $15.6 million as the latest value for Q1 2025.

  • On a quarterly basis, Accumulated Depreciation rose 37.16% to $15.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $15.6 million, a 37.16% increase, with the full-year FY2024 number at $13.6 million, up 32.14% from a year prior.
  • Accumulated Depreciation was $15.6 million for Q1 2025 at Maxcyte, up from $13.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $15.6 million in Q1 2025 to a low of $3.6 million in Q2 2021.
  • A 5-year average of $9.0 million and a median of $10.3 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 63.92% in 2023, then soared 32.14% in 2024.
  • Maxcyte's Accumulated Depreciation stood at $4.4 million in 2021, then surged by 43.51% to $6.3 million in 2022, then skyrocketed by 63.92% to $10.3 million in 2023, then soared by 32.14% to $13.6 million in 2024, then grew by 14.92% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Accumulated Depreciation are $15.6 million (Q1 2025), $13.6 million (Q4 2024), and $11.9 million (Q2 2024).